Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 134

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 134
---
 Placement Warrants (95,186 shares as of January 
 8, 2025);                                                                                                                        |

| ● | 87,879                                                                                                                               
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings of our Series A Preferred Stock, Series 
 B Preferred Stock and Series C Preferred Stock (335,802 shares as of January 8, 2025); and                                           |

| ● | 1,345,679                                                                                                                                 
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred         
 Stock, including 497,977 shares issuable upon the exercise of Preferred Warrants (626,953 shares of Common Stock issuable upon conversion 
 of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock as of January 8, 2025).                           |

<div align='center'>71

DILUTION</div>

If you invest in the Common
Stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering
price per share of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Offered Common Warrants, and the pro forma
net tangible book value per share of Common Stock immediately after this offering. All information in this section has been presented
giving retroactive effect to the Reverse Stock Split.

As of September 30, 2024,
our historical net negative tangible book value was $(3.7) million or $(2.48) per share of Common Stock. Historical net tangible book
value per share of Common Stock represents our total tangible assets less total liabilities, divided by the number of shares of Common
Stock outstanding as September 30, 2024. Giving effect to (i) the exercise of 2,462 Preferred Warrants for 2,462 shares of Series A Preferred
Stock and the receipt of the cash proceeds of such exercises, (ii) the conversion of 3,484 shares of Series A Preferred Stock into 759,369
shares of Common Stock, including the shares of Series A Preferred Stock set forth in clause (i), (iii) the conversion of 213 shares
of Series B Preferred Stock into 41,376 shares of Common Stock, and (iv) the issuance of 436,383 shares of Common Stock pursuant to the
Keystone Equity Financing, in each case from October 1, 2024 through January 8, 2025,